Sertraline

Generic Name: Sertraline

Brand Names: Zoloft

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇Cl_₂N

CAS Number: 79617-96-2

Unique Ingredient Identifier: QUC7NX6WMB

Background: Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
...

Indication: Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety di...

Associated Conditions: Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)

Associated Therapies: -

Clinical Trials

Anxiety Disorders and Depression Treatment Market to Reach

The Anxiety Disorders and Depression Treatment Market was valued at USD 12.2 billion in 2023 and is projected to reach USD 16.65 billion by 2032, growing at a CAGR of 3.53%. This growth is driven by the rising prevalence of anxiety disorders and depression, advancements in pharmaceutical therapies, and increased awareness and destigmatization of mental health issues.

clinicaltrialsarena.com

2 months ago

Supernus' depression drug improved symptoms in two hours in Phase IIa study

Supernus Pharmaceuticals' SPN-820 showed rapid and substantial effects in a Phase IIa trial for major depressive disorder, with a clinically meaningful improvement on the HAM-D6 scale and a significant reduction in suicidal ideation. SPN-820 is designed as a rapid-acting treatment, contrasting with the slower effects of SSRIs, and is well-tolerated with common AEs like headache and nausea. A Phase IIb study is ongoing, with results expected in H1 2025.

Related Clinical Trials:

Open-Label of SPN-820 in Adults With Major Depressive Disorder

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

insideprecisionmedicine.com

3 months ago

Psilocybin Provides Comparable Long-Term Antidepressant Effects as SSRIs

A study at ECNP Congress in Milan found psilocybin, from 'magic mushrooms,' as effective as escitalopram in treating depression, with potential long-term benefits. Psilocybin users reported better psychosocial functioning and life meaning over six months. Psilocybin could offer an alternative for non-responders to SSRIs, though its use requires controlled environments.

drugs.com

3 months ago

Psilocybin Equals or Exceeds SSRI Antidepressants at Easing Depression

Psilocybin, in magic mushrooms, shows similar depression relief to SSRI antidepressants like Lexapro, with additional long-term benefits of greater life meaning and psychological connectedness, according to a clinical trial. However, psilocybin is experimental and should not be self-administered.

eurekalert.org

3 months ago

Study shows psychedelic drug psilocybin gives

Psilocybin and SSRI escitalopram showed similar long-term depression symptom improvements, but psilocybin offered additional benefits in psychosocial functioning, meaning in life, and psychological connectedness over 6 months. Psilocybin also improved sexual drive, unlike SSRIs, suggesting potential additional mental health benefits.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy